Newsbenzinga
Climb Bio And Mabworks Report Phase 1 Data Supporting Quarterly CLYM116/MIL116 Dosing For IgA Nephropathy; Phase 3 Trial Expected In 2027
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…